Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells

Christian Koch; Giulia Montrasio; Benedikt Florian Scherr; Roman Schimmer; Christian M Matter; Karl Philipp Bühler; Markus G Manz; Antonia M S Müller

doi:10.1016/j.jaccao.2022.07.012

Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells

JACC CardioOncol. 2022 Dec 20;4(5):708-712. doi: 10.1016/j.jaccao.2022.07.012. eCollection 2022 Dec.

Authors

Christian Koch¹, Giulia Montrasio², Benedikt Florian Scherr³, Roman Schimmer¹, Christian M Matter², Karl Philipp Bühler³, Markus G Manz¹, Antonia M S Müller^{1

4}

Affiliations

¹ Department of Medical Oncology and Hematology, University and University Hospital Zurich, Zurich, Switzerland.
² Department of Cardiology, University Hospital Zurich, Zurich, Switzerland.
³ Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.
⁴ Department of Blood Group Serology and Transfusion Medicine, Medical University Vienna, Vienna, Austria.

No abstract available

Keywords: AV, atrioventricular; CAR T cell therapy; CAR, chimeric antigen receptor; CNS, central nervous system; CRS, cytokine release syndrome; ICU, intensive care unit; LV, left ventricular; arrhythmia; cardiotoxicity; lymphoma; myocardial edema.

Publication types

Review